Background: The phenomenon of deformation of devices for closure of intracardiac defects in catheterization has been reported, but not of devices for closure of patent ductus arteriosus.
Objective: to report a case of deformation of a relatively new type of device for closure of patent ductus arteriosus.
Methods: report an adult with hypertensive patent ductus arteriosus and a positive balloon occlusion test will be presented, in whom the occlusion was attempted with an Occlutech®-PDA device.
Results: Upon delivery, the device took the shape of a “horn” instead of a “champagne cork” (usual appearance), so it was extracted prior to it is release and the procedure was carried out with another device.
Conclusion: To our knowledge, no deformation during the delivery transcatheter of the Occlutech®-PDA device has been published. Adverse events related to new technologies, as in our case, should be reported as soon as possible, since it can help manufacturers to improve their quality and provide greater safety to patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590818 | PMC |
| http://dx.doi.org/10.31053/1853.0605.v79.n3.32651 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary Atresia with Ventricular Septal Defect without Major Aorto-Pulmonary Collateral Arteries: Echocardiography and the Role of Computed Tomography and Magnetic Resonance Imaging.
World J Pediatr Congenit Heart Surg
January 2025
Department of Pediatrics, Inova Health System, Falls Church, VA, USA.
Pulmonary atresia with ventricular septal defect (PA-VSD) is usually diagnosed by transthoracic or fetal echocardiography, with the prenatal diagnosis being feasible and accurate if fetal cardiology services are available. The limitations of transthoracic echocardiography (TTE) in the evaluation of PA-VSD include the complete evaluation of the pulmonary arteries and patent ductus arteriosus, quantitative evaluation of the right ventricle size and function, and delineation of associated cardiac anomalies such as coronary artery anomalies, anomalies of systemic or pulmonary venous return, and complex arch anomalies. Echocardiography also has limitations in evaluating hemodynamics such as flow volumes, shunts, and regurgitant fraction.
View Article and Find Full Text PDFUrinary Acetaminophen Metabolites and Clinical Outcomes in Extremely Premature Infants.
Am J Perinatol
January 2025
Pediatrics, University of California San Francisco, San Francisco, United States.
Objective: Extremely premature infants are treated with acetaminophen (APAP) for pain and patent ductus arteriosus. High doses of APAP in adults are toxic, and a recent study found an association between APAP metabolite levels in mothers' breast milk and both bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in their premature infants. In this study, we determined levels of APAP metabolites in urine of infants at high risk for BPD and ROP.
View Article and Find Full Text PDFThe Critical Role of Pulse Oximetry Screening for Congenital Heart Disease and Patent Ductus Arteriosus in Newborns.
Cureus
December 2024
Pediatrics, Alessandrescu-Rusescu National Institute of Mother and Child Health, Bucharest, ROU.
Introduction: Congenital heart disease (CHD) is diagnosed with high prevalence. Pulse oximetry and clinical examination are screening tools to aid in obtaining a CHD diagnosis.
Materials And Methods: We conducted a retrospective longitudinal study over three years, screening 1188 newborns admitted to the neonatal intensive care unit (NICU) during the first 72 hours of life.
Double Outlet Right Ventricle: A Rare Finding in a 15-Month-Old Female With Failure to Thrive.
Clin Case Rep
January 2025
Department of Radiology and Radiotherapy, School of Medicine, College of Health Sciences Makerere University Kampala Uganda.
Double outlet right ventricle (DORV) is a rare congenital heart defect where both the aorta and pulmonary artery originate from the right ventricle, often accompanied by additional cardiac anomalies to mitigate circulatory imbalance, though such compensations usually fail. We report a 15-month-old infant with recurrent respiratory infections and poor weight gain, referred for computed tomography angiography. Physical examination showed a small, non-syndromic infant with pallor, tachypnea, irritability, and finger clubbing.
View Article and Find Full Text PDFDo Major Pharmacovigilance Databases Support Evidence of Second Trimester NSAID and Third Trimester Paracetamol Fetotoxicity?
Pharmaceuticals (Basel)
November 2024
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Clinical Pharmacology and Toxicology, Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Augustenburger Platz 1, 13353 Berlin, Germany.
Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used during pregnancy. Due to their fetotoxicity, NSAIDs are contraindicated during the third trimester. There is ongoing controversy about the extent to which NSAIDs may cause cardiovascular and renal impairment in the fetus earlier in the second trimester.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!